biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Jan 01, 2016 6:21pm

130 Views

Post# 24424140

RE:RE:Best Guesses for 2016

Oilpatch: ".... J.d and kayakers....you both thought bti would have been scooped up before now....when im home ill find the posts...."

Ok, I'm looking forward to reading what you come up with. For a looong while, I've thought we would a very slim chance for a buyout without clinical data. For example, here's what I wrote on 2015-09-29....

"....A buyout by Q2 2016? I give that about a 1% chance. IMO it's unlikely without clinical data, and I don't expect that until 2017...."

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!